Last reviewed · How we verify
WHO-recommended SOC Itraconazole
WHO-recommended SOC Itraconazole is a Triazole antifungal Small molecule drug developed by University of Minnesota. It is currently in Phase 3 development for Treatment of various fungal infections, including aspergillosis, candidiasis, and histoplasmosis.
Itraconazole inhibits the synthesis of ergosterol, an essential component of fungal cell membranes.
Itraconazole inhibits the synthesis of ergosterol, an essential component of fungal cell membranes. Used for Treatment of various fungal infections, including aspergillosis, candidiasis, and histoplasmosis.
At a glance
| Generic name | WHO-recommended SOC Itraconazole |
|---|---|
| Sponsor | University of Minnesota |
| Drug class | Triazole antifungal |
| Target | Lanosterol 14α-demethylase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
By inhibiting the enzyme lanosterol 14α-demethylase, itraconazole prevents the conversion of lanosterol to ergosterol, ultimately disrupting fungal cell membrane integrity and leading to cell death.
Approved indications
- Treatment of various fungal infections, including aspergillosis, candidiasis, and histoplasmosis
Common side effects
- Hepatotoxicity
- Rash
- Nausea
Key clinical trials
- Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WHO-recommended SOC Itraconazole CI brief — competitive landscape report
- WHO-recommended SOC Itraconazole updates RSS · CI watch RSS
- University of Minnesota portfolio CI
Frequently asked questions about WHO-recommended SOC Itraconazole
What is WHO-recommended SOC Itraconazole?
How does WHO-recommended SOC Itraconazole work?
What is WHO-recommended SOC Itraconazole used for?
Who makes WHO-recommended SOC Itraconazole?
What drug class is WHO-recommended SOC Itraconazole in?
What development phase is WHO-recommended SOC Itraconazole in?
What are the side effects of WHO-recommended SOC Itraconazole?
What does WHO-recommended SOC Itraconazole target?
Related
- Drug class: All Triazole antifungal drugs
- Target: All drugs targeting Lanosterol 14α-demethylase
- Manufacturer: University of Minnesota — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Treatment of various fungal infections, including aspergillosis, candidiasis, and histoplasmosis
- Compare: WHO-recommended SOC Itraconazole vs similar drugs
- Pricing: WHO-recommended SOC Itraconazole cost, discount & access